Patents by Inventor Audris Huang

Audris Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER
    Publication number: 20230322803
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: March 22, 2021
    Publication date: October 12, 2023
    Inventors: Andrew P. Degnan, Godwin Kwame Kumi, Andrew J. Tebben, Audris Huang, Peter Kinam Park, Donna M. Bilder, Emily Charlotte Cherney, Ashok Vinayak Purandare
  • PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS
    Publication number: 20230303527
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein R1, R2, R4, R6, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: June 8, 2023
    Publication date: September 28, 2023
    Inventors: Yan Chen, Godwin Kwame Kumi, Audris Huang, Satheesh Kesavan Nair, Bharat Dinkar Shimpukade, Suresh Babu Vishwa Krishna Penmetsa, James Aaron Balog
  • Pyridinyl substituted oxoisoindoline compounds
    Patent number: 11718601
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein R1, R2, R4, R6, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: August 8, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Chen, Godwin Kwame Kumi, Audris Huang, Satheesh Kesavan Nair, Bharat Dinkar Shimpukade, Suresh Babu Vishwa Krishna Penmetsa, James Aaron Balog
  • Compounds useful as inhibitors of helios protein
    Patent number: 11548870
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: Z is CR6R6 or C?O; Ring A is: and R1, R2, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: January 10, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew P. Degnan, Godwin Kwame Kumi, Audris Huang, James Aaron Balog, Ashok Vinayak Purandare, Weifang Shan, Guo Li
  • PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS
    Publication number: 20220324840
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein R1, R2, R4, R6, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: April 5, 2022
    Publication date: October 13, 2022
    Inventors: Yan Chen, Godwin Kwame Kumi, Audris Huang, Satheesh Kesavan Nair, Bharat Dinkar Shimpukade, Suresh Babu Vishwa Krishna Penmetsa, James Aaron Balog
  • RADIOLIGANDS FOR IMAGING THE ID01 ENZYME
    Publication number: 20220305144
    Abstract: The present invention relates to radiolabeled IDO1 inhibitors or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of IDO enzymes in mammals.
    Type: Application
    Filed: April 18, 2022
    Publication date: September 29, 2022
    Inventors: David J. Donnelly, Erin Lee Cole, Richard Charles Burrell, Wesley A. Turley, Alban J. Allentoff, Michael Arthur Wallace, James Aaron Balog, Audris Huang, Mette Skinbjerg
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11427610
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: August 30, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Yufen Zhao, Libing Chen, Audris Huang
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 11337970
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: May 24, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Emily Charlotte Cherney, Weifang Shan, Liping Zhang, Susheel Jethanand Nara, Audris Huang, James Aaron Balog
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
    Publication number: 20210290613
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: August 25, 2017
    Publication date: September 23, 2021
    Inventors: Emily Charlotte CHERNEY, Weifang SHAN, Liping ZHANG, Susheel Jethanand NARA, Audris HUANG, James Aaron BALOG
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20210253624
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: October 16, 2018
    Publication date: August 19, 2021
    Inventors: Brian E. FINK, Yufen Zhao, Libing Chen, Audris Huang
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 11066392
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: July 20, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Liping Zhang, Audris Huang, Weifang Shan, David K. Williams, Xiao Zhu, Weiwei Guo
  • COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN
    Publication number: 20210147383
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: Z is CR6R6 or C?O; Ring A is: and R1, R2, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: November 18, 2020
    Publication date: May 20, 2021
    Inventors: Andrew P. DEGNAN, Godwin Kwame Kumi, Audris Huang, James Aaron Balog, Ashok Vinayak Purandare, Weifang Shan, Guo Li
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 10633342
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: April 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Emily Charlotte Cherney, Weifang Shan, Liping Zhang, David K. Williams, Weiwei Guo, Audris Huang, James Aaron Balog
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
    Publication number: 20200095231
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: May 10, 2018
    Publication date: March 26, 2020
    Inventors: James Aaron BALOG, Emily Charlotte CHERNEY, Liping ZHANG, Audris HUANG, Weifang SHAN, David K. WILLIAMS, Xiao ZHU, Weiwei GUO
  • Immunoregulatory agents
    Patent number: 10533014
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: January 14, 2020
    Assignee: FLEXUS BIOSCIENCES, INC.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Emily Charlotte Cherney, Weifang Shan, Audris Huang
  • RADIOLIGANDS FOR IMAGING THE IDO1 ENZYME
    Publication number: 20190282714
    Abstract: The present invention relates to radiolabeled IDO1 inhibitors or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of IDO enzymes in mammals.
    Type: Application
    Filed: July 18, 2017
    Publication date: September 19, 2019
    Inventors: David J. Donnelly, Erin Lee Cole, Richard Charles Burrell, Wesley A. Turley, Alban J. Allentoff, Michael Arthur Wallace, James Aaron Balog, Audris Huang, Mette Skinbjerg
  • Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
    Patent number: 10399932
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: September 3, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Audris Huang, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla
  • Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
    Patent number: 10399933
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: September 3, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Weiwei Guo, Audris Huang, Jay A. Markwalder, Weifang Shan, David K. Williams, Susheel Jethanand Nara, Saumya Roy
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
    Publication number: 20190135758
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 9, 2019
    Inventors: Emily Charlotte CHERNEY, Weifang SHAN, Liping ZHANG, David K. WILLIAMS, Weiwei GUO, Audris HUANG, James Aaron BALOG
  • Immunoregulatory agents
    Patent number: 10206893
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: February 19, 2019
    Assignee: Flexus Biosciences, Inc.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Steven P. Seitz, Emily Charlotte Cherney, Liping Zhang, Weifang Shan, Weiwei Guo, Audris Huang